Pozelimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.

**Synonyms:** - POZELIMAB - REGN 3918 - REGN-3918 - REGN3918 - WHO 10945